Q2 EPS Estimates for UroGen Pharma Boosted by HC Wainwright

UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) - Investment analysts at HC Wainwright increased their Q2 2025 earnings estimates for shares of UroGen Pharma in a research note issued to investors on Thursday, May 22nd. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.74) for the quarter, up from their previous forecast of ($0.75). HC Wainwright currently has a "Neutral" rating on the stock. The consensus estimate for UroGen Pharma's current full-year earnings is ($3.12) per share. HC Wainwright also issued estimates for UroGen Pharma's Q3 2025 earnings at ($0.65) EPS, Q4 2025 earnings at ($0.64) EPS, FY2025 earnings at ($2.95) EPS, Q1 2026 earnings at ($0.63) EPS, Q2 2026 earnings at ($0.56) EPS, Q3 2026 earnings at ($0.50) EPS, Q4 2026 earnings at ($0.45) EPS and FY2026 earnings at ($2.14) EPS.

Several other research analysts also recently commented on URGN. D. Boral Capital reissued a "buy" rating and issued a $25.00 price target on shares of UroGen Pharma in a report on Thursday, May 8th. LADENBURG THALM/SH SH assumed coverage on shares of UroGen Pharma in a research report on Wednesday, February 19th. They issued a "buy" rating and a $31.00 target price on the stock. The Goldman Sachs Group decreased their price objective on shares of UroGen Pharma from $16.00 to $3.00 and set a "neutral" rating on the stock in a research report on Thursday, May 22nd. Scotiabank started coverage on shares of UroGen Pharma in a research note on Wednesday, April 16th. They set a "sector outperform" rating and a $23.00 target price on the stock. Finally, Guggenheim lowered their target price on shares of UroGen Pharma from $40.00 to $15.00 and set a "buy" rating for the company in a report on Friday, May 23rd. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $27.43.

UroGen Pharma Price Performance

NASDAQ:URGN traded down $0.08 during trading hours on Monday, hitting $3.97. The stock had a trading volume of 1,315,959 shares, compared to its average volume of 688,564. The company has a 50 day simple moving average of $9.56 and a two-hundred day simple moving average of $10.50. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77. UroGen Pharma has a one year low of $3.42 and a one year high of $20.70. The firm has a market capitalization of $183.09 million, a price-to-earnings ratio of -1.25 and a beta of 0.66.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.09). The company had revenue of $20.25 million for the quarter, compared to the consensus estimate of $22.71 million.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. CWM LLC lifted its stake in shares of UroGen Pharma by 6,047.1% during the 1st quarter. CWM LLC now owns 5,225 shares of the company's stock valued at $58,000 after buying an additional 5,140 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of UroGen Pharma during the 4th quarter valued at $59,000. Lazard Asset Management LLC purchased a new position in shares of UroGen Pharma during the 4th quarter valued at $67,000. GAMMA Investing LLC lifted its stake in shares of UroGen Pharma by 6,908.4% during the 1st quarter. GAMMA Investing LLC now owns 7,499 shares of the company's stock valued at $83,000 after buying an additional 7,392 shares in the last quarter. Finally, Aquatic Capital Management LLC purchased a new position in shares of UroGen Pharma during the 4th quarter valued at $101,000. Hedge funds and other institutional investors own 91.29% of the company's stock.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.